The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
The xc− cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance
Open accessAbstract
The x(c)(-) cystine transporter enhances biosynthesis of glutathione, a tripeptide thiol important in drug resistance and cellular defense against oxidative stress, by enabling cellular uptake of cystine, a rate-limiting precursor. Because it is known to regulate glutathione levels and growth of various cancer cell types, and is expressed in the pancreas, we postulate that it is involved in growth and drug resistance of pancreatic cancer. To examine this, we characterised expression of the x(c)(-) transporter in pancreatic cancer cell lines, MIA PaCa-2, PANC-1 and BxPC-3, as subjected to cystine-depletion and oxidative stress. The results indicate that these cell lines depend on x(c)(-)-mediated cystine uptake for growth, as well as survival in oxidative stress conditions, and can modulate x(c)(-) expression to accommodate growth needs. Immunohistochemical analysis showed that the transporter was differentially expressed in normal pancreatic tissues and overexpressed in pancreatic cancer tissues from two patients. Furthermore, gemcitabine resistance of cells was associated with elevated x(c)(-) expression and specific x(c)(-) inhibition by monosodium glutamate led to growth arrest. The results suggest that the x(c)(-) transporter by enhancing glutathione biosynthesis plays a major role in pancreatic cancer growth, therapy resistance and represents a potential therapeutic target for the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glutathione in Cancer Biology and Therapy
Estrela, J. M., Ortega, A., & Obrador, E. (2006) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360500523878 · Cited by 1,041
Gout, P., Buckley, A., Simms, C., & Bruchovsky, N. (2001) · Leukemia · doi:10.1038/sj.leu.2402238 · Cited by 640 · cited 3×
“…inhibition of the xc transporter in cancer cells depending on extracellular cystine/cysteine for growth and viability, can lead to reduced uptake of this amino acid with subsequent depletion of intracellular GSH levels and growth arrest (Gout et al, 2001; Chung et al, 2005; Doxsee et al, 2007).”
BackgroundSelf-citationThe x cystine/glutamate antiporter: A potential target for therapy of cancer and other diseases
Lo, M., Wang, Y., & Gout, P. W. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21366 · Cited by 399 · cited 4×
“For such malignancies the xc transporter therefore represents a potential therapeutic target (Lo et al, 2008).”
BackgroundInfluentialSelf-citationCystine requirement of continuous human lymphoid cell lines of normal and leukemic origin
Iglehart, J. K., York, R. M., Modest, A. P., Lazarus, H., & Livingston, D. M. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)66953-x · Cited by 62
Cited by
Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.042 · Cited by 18,691
Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy
Koppula, P., Zhuang, L., & Gan, B. (2021) · Protein & Cell · doi:10.1007/s13238-020-00789-5 · Cited by 2,487
Emerging Mechanisms and Disease Relevance of Ferroptosis
Stockwell, B. R., Jiang, X., & Gu, W. (2020) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.02.009 · Cited by 1,099
Lewerenz, J., Hewett, S. J., Huang, Y., Lambros, M., Gout, P. W., Kalivas, P. W., Massie, A., Smolders, I., Methner, A., Pergande, M., et al. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4391 · Cited by 978
Self-citationMyeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine
Srivastava, M. K., Sinha, P., Clements, V. K., Rodriguez, P., & Ostrand-Rosenberg, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2587 · Cited by 949
Lieu, E. L., Nguyen, T., Rhyne, S., & Kim, J. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0375-3 · Cited by 818
Ferroptosis, a new form of cell death, and its relationships with tumourous diseases
Yu, H., Guo, P., Xie, X., Wang, Y., & Chen, G. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13008 · Cited by 710
Self-citationDo Van, B., Gouel, F., Jonneaux, A., Timmerman, K., Gelé, P., Pétrault, M., Bastide, M., Laloux, C., Moreau, C., Bordet, R., et al. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.05.011 · Cited by 689
HSPA5 Regulates Ferroptotic Cell Death in Cancer Cells
Zhu, S., Zhang, Q., Sun, X., Zeh, H. J., Lotze, M. T., Kang, R., & Tang, D. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1979 · Cited by 576
Conrad, M., & Sato, H. (2012) · Amino Acids · doi:10.1007/s00726-011-0867-5 · Cited by 598
Timmerman, L. A., Holton, T., Yuneva, M., Louie, R. J., Padró, M., Daemen, A., Hu, M., Chan, D. A., Ethier, S. P., van ‘t Veer, L. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.020 · Cited by 573
“…due to tumor defects far removed from direct glutamine interaction. xCT Is a Compelling Therapeutic Target for Triple-Negative Tumors Inhibitor and RNAi studies reveal xCT induction as the dominant means of increasing cystine acquisition to accelerate GSH synthesis (reviewed in Lo et al., 2008a).”
Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells
Eling, N., Reuter, L., Hazin, J., Hamacher-Brady, A., & Brady, N. R. (2015) · Oncoscience · doi:10.18632/oncoscience.160 · Cited by 524
“Intriguingly, PDAC redox homeostasis is dependent on cystine uptake via the xc − transporter [29], which is a key participant in ferroptosis [30], suggesting an inherent sensitivity of PDAC to this iron-dependent mode of programmed necrosis.”
BackgroundResultNew aspects of amino acid metabolism in cancer
Vettore, L., Westbrook, R. L., & Tennant, D. A. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0620-5 · Cited by 502
Bhutia, Y. D., Babu, E., Ramachandran, S., & Ganapathy, V. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3745 · Cited by 481
A Dual Role of Heme Oxygenase-1 in Cancer Cells
Chiang, S.-K., Chen, S.-E., & Chang, L.-C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010039 · Cited by 465
Hu, K., Li, K., Lv, J., Feng, J., Chen, J., Wu, H., Cheng, F., Jiang, W., Wang, J., Pei, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci124049 · Cited by 404
xCT: A Critical Molecule That Links Cancer Metabolism to Redox Signaling
Liu, J., Xia, X., & Huang, P. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.08.021 · Cited by 347
Unraveling the Potential Role of Glutathione in Multiple Forms of Cell Death in Cancer Therapy
Lv, H., Zhen, C., Liu, J., Yang, P., Hu, L., & Shang, P. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/3150145 · Cited by 320
Ferritinophagy/ferroptosis: Iron‐related newcomers in human diseases
Tang, M., Chen, Z., Wu, D., & Chen, L. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26954 · Cited by 290
Cysteine dioxygenase 1 mediates erastin-induced ferroptosis in human gastric cancer cells
Hao, S., Yu, J., He, W., Huang, Q., Zhao, Y., Liang, B., Zhang, S., Wen, Z., Dong, S., Rao, J., et al. (2017) · Neoplasia · doi:10.1016/j.neo.2017.10.005 · Cited by 276
The Influence of Metabolism on Drug Response in Cancer
Zaal, E. A., & Berkers, C. R. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00500 · Cited by 272
The Role of Cystine/Glutamate Antiporter SLC7A11/xCT in the Pathophysiology of Cancer
Jyotsana, N., Ta, K. T., & DelGiorno, K. E. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.858462 · Cited by 272
Lu, H., Samanta, D., Xiang, L., Zhang, H., Hu, H., Chen, I., Bullen, J. W., & Semenza, G. L. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1513433112 · Cited by 269
Stem Cell Factor SOX2 Confers Ferroptosis Resistance in Lung Cancer via Upregulation of SLC7A11
Wang, X., Chen, Y., Wang, X., Tian, H., Wang, Y., Jin, J., Shan, Z., Liu, Y., Cai, Z., Tong, X., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0567 · Cited by 264
Self-citationInterfering with ROS Metabolism in Cancer Cells: The Potential Role of Quercetin
Gibellini, L., Pinti, M., Nasi, M., De Biasi, S., Roat, E., Bertoncelli, L., & Cossarizza, A. (2010) · Cancers · doi:10.3390/cancers2021288 · Cited by 263
Guan, J., Lo, M., Dockery, P., Mahon, S., Karp, C. M., Buckley, A. R., Lam, S., Gout, P. W., & Wang, Y.-Z. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0894-4 · Cited by 134
Self-citationAlternative fuels for cancer cells
Keenan, M. M., & Chi, J.-T. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000104 · Cited by 131
Lo, M., Ling, V., Low, C., Wang, Y. Z., & Gout, P. W. (2010) · Current Oncology · doi:10.3747/co.v17i3.485 · Cited by 120
Self-citation
Metadata
- Authors
- Lo, M., Ling, V, Wang, Y. Z., & Gout, P. W.
- Venue
- British Journal of Cancer
- Published
- 2008-07-22
- Volume
- 99
- Issue
- 3
- Pages
- 464-472
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2155863110
- Cited by
- 221
- References
- 4
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.